Immune cells in blood and tumors of adults with malignant brain tumors
Studies immune cells in blood and tumor tissue of adults with malignant brain tumors.
Key facts
- Who runs it
- Pietro Mortini, MD, Prof.
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Characterization of Circulating and Tumor-infiltrating Immune Cells in Malignant Brain Tumors
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 1 Aug 2022
- Expected to end
- 1 Aug 2029
- Type of study
- Observational
- Treatments tested
- Circulating leukocytes immunophenotype
- Tumor sampling
- Record updated
- 11 June 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a malignant brain tumor that started in the brain or spread there, who need brain surgery or related treatment. Blood and tumor samples will be studied.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Primary or secondary (spread from elsewhere) malignant brain tumor, newly diagnosed, needing neurosurgical treatment (radiosurgery, stereotactic biopsy or surgery).
Main reasons for not taking part
- People under 18 years cannot join.
- People not able to give informed consent cannot join.
- People who do not need neurosurgical treatment cannot join.
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Adult patients (≥18 years)
- Able to express informed consent
- With primary or secondary malignant brain tumor
- Requiring neurosurgical treatment (radiosurgery, stereotactic biopsy, surgery)
Who cannot take part
- Patients who do not meet inclusion criteria
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this observational study is to characterize the circulating leukocyte profile and the immune T cells distribution within the tumor in patients with malignant brain tumors and to correlate these findings with the oncological outcome.
Read full original descriptionShow less
Participants will be subjected to blood sampling before surgery and for 12 months of follow-up. Additional sampling and analysis will be performed on tumor samples.
The group in the trial
- Included patients
The study population will comprise 200 (two hundred) adult patients candidate to neurosurgical treatment for newly diagnosed malignant brain tumors, able to express an informed consent.
Treatment: Circulating leukocytes immunophenotype and Tumor sampling
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Immunophenotype Characterization of Circulating and Tumor Infiltrating Immune Cells in Malignant Brain Tumors.
- Plain-language title
- Immune cells in blood and tumors of adults with malignant brain tumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 11 June 2025